Aclaris Therapeutics (8AT) Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
8AT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aclaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.70 |
| 52 Week High | US$4.31 |
| 52 Week Low | US$1.19 |
| Beta | 0.80 |
| 1 Month Change | -2.73% |
| 3 Month Change | 17.30% |
| 1 Year Change | 207.22% |
| 3 Year Change | n/a |
| 5 Year Change | -75.32% |
| Change since IPO | -87.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8AT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.5% | 1.1% | 2.4% |
| 1Y | 207.2% | 27.8% | 3.9% |
Return vs Industry: 8AT exceeded the German Pharmaceuticals industry which returned 23.1% over the past year.
Return vs Market: 8AT exceeded the German Market which returned 3.3% over the past year.
Price Volatility
| 8AT volatility | |
|---|---|
| 8AT Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 8AT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8AT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 71 | Neal Walker | www.aclaristx.com |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics, Inc. Fundamentals Summary
| 8AT fundamental statistics | |
|---|---|
| Market cap | €527.40m |
| Earnings (TTM) | -€60.61m |
| Revenue (TTM) | €7.28m |
Is 8AT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8AT income statement (TTM) | |
|---|---|
| Revenue | US$8.37m |
| Cost of Revenue | US$64.27m |
| Gross Profit | -US$55.91m |
| Other Expenses | US$13.76m |
| Earnings | -US$69.66m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | -668.18% |
| Net Profit Margin | -832.58% |
| Debt/Equity Ratio | 0% |
How did 8AT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 20:30 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aclaris Therapeutics, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Donald Ellis | Citizens JMP Securities, LLC |
| Adam Vogel | Craig-Hallum Capital Group LLC |